Delving Into New Two-year Bimekizumab (Bimzelx, UCB) Data in Hidradenitis Suppurativa (HS) With Christopher Sayed, MD
More than 63% of hidradenitis suppurativa (HS) patients who took bimekizumab (Bimzelx, UCB) for two years had no or mild skin pain, a substantial improvement from 10% at baseline. Of 425 HS patients with one or more draining tunnel (DT) at baseline, 55.7% had no DTs at two years of treatment. Christopher Sayed, MD, a Dermatologist at the University of […]